Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings

International Journal of Laboratory Hematology

Volumn 37, Issue 5, 2015, Pages 661-667

  Ferdowsi, S ^a   Atarodi, K ^a   Amirizadeh, N ^a   Toogeh, G ^b   Azarkeivan, A ^a   Shirkoohi, R ^b   Faranoush, M ^a   Vaezi, M ^c   Alimoghaddam, K ^c   Ghavamzadeh, A ^c   Naghadeh, H Teimori ^a   Ghaffari, S H ^c  

^a HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Essential thrombocythemia; JAK2 V617F allele burden; MicroRNAs; Polycythemia vera

Indexed keywords

JANUS KINASE 2; MICRORNA; MICRORNA 125; MICRORNA 125A-3P; MICRORNA 125A-5P; MICRORNA 125B-3P; MICRORNA 125B-5P; UNCLASSIFIED DRUG; MIRN125 MICRORNA, HUMAN;

ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD EXAMINATION; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; MALE; MUTATION; THROMBOCYTHEMIA, ESSENTIAL;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; HEMATOLOGIC TESTS; HUMANS; JANUS KINASE 2; MALE; MICRORNAS; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84941743766     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12381     Document Type: Article

References (32)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171-91.
2. Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22:1299-307.
3. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007;35:1657-67.
4. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008;93:1009-16.
5. Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V, Poli G, Zini R, Ferrari S, Manfredini R, Bosi A, Vannucchi AM. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 2007;35:1708.e1-e12.
6. Zhan H, Cardozo C, Raza A. MicroRNAs in myeloproliferative neoplasms. Br J Haematol 2013;161:471-83.
7. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discovery 2010;9:775-89.
8. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci 2010;107:14235-40.
9. Ooi AL, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci 2010;107:21505-10.
10. Bousquet MHM, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA 2010;107:21558-63.
11. Guo S, Bai H, Megyola CM, Halene S, Krause DS, Scadden DT, Lu J. Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. Proc Natl Acad Sci 2012;109:16636-41.
12. Zhan H, Cardozo C, Yu W, Wang A, Moliterno AR, Dang CV, Spivak JK. MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis 2013;50:190-5.
13. Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
14. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schuitheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
15. Fiedler SD, Carletti MZ, Christenson LK. Quantitative RT-PCR methods for mature microRNA expression analysis. Methods Mol Biol 2010;630:49-64.
16. -ΔΔCT method. Methods 2001;25:402-8.
17. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, Lippert E, Talmant P, Lafage Pochitaloff M, Leroux D, Gervais C, Viquie F, Lai JL, Terre C, Beverlo B, Sambani C, Hagemeijer A, Marynen P, Delsol G, Dastugue N, Mecucci C, Brousset P. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2; 11)(p21; q23) translocation. J Exp Med 2008;205:2499-506.
18. Enomoto Y. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011;25:1849-56.
19. Jh K. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010;24:478-90.
20. Gefen N. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 2010;24:89-96.
21. Zhang H, Luo X-Q, Feng D-D, Zhang X-J, Wu J, Zheng Y-S, Chen X, Xu L, Chen YQ. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011;10:108.
22. Chaudhuri AA, So AY-L, Mehta A, Minisandram A, Sinha N, Jonsson VD, Rao DS, OConnell RM, Baltimore D. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci 2012;109:4233-8.
23. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83.
24. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. ASH Educ Prog Book 2005;2005:195-200.
25. Lin X, Rice K, Buzzai M, Hexner E, Costa F, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, Licht JD. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 2013;27:344-52.
26. Park SH, Chi H-S, Cho Y-U, Jang S, Park C-J. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm. Blood Res 2013;48:128-32.
27. Ancochea À, Álvarez-Larrán A, Morales-Indiano C, García-Pallarols F, Martínez-Avilés L, Angona A, Senin A, Bellosillo B, Besses C. The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera. Br J Haematol 2014;167:411-17.
28. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, Cross NC. JAK2 V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011;35:177-82.
29. Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, Martinelli G, Bosi A, Vannucchi AM. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood 2011;117:6923-7.
30. Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W, Giraudier S, Constantinescu SN. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010;116:437-45.
31. Slezak S, Jin P, Caruccio L, Ren J, Bennett M, Zia N, Adams S, Wang E, Ascensao J, Schechter G, Stroncek D. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and-133a. J Transl Med 2009;7:39.
32. Benati M, Montagnana M, Danese E, De Matteis G, Veneri D, Paviati E, Guidi GC. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. Clin Chem Lab Med 2015;53:1005-11.